Mr Richard T. Bryan MBChB PhD MRCS FAcadTM

Mr Richard T. Bryan

Institute of Cancer and Genomic Sciences
Senior Research Fellow

Contact details

Institute of Cancer and Genomic Sciences
Robert Aitken Institute for Clinical Research
College of Medical and Dental Sciences
University of Birmingham
B15 2TT

Rik Bryan is a former clinical urologist, and now a full-time bladder cancer research academic. He is the Chief Investigator of the Bladder Cancer Prognosis Programme (BCPP), the SELENIB clinical trial, and POUT-T. He leads the Bladder Cancer Group in the Institute of Cancer & Genomic Sciences. The group has a particular interest in the genomics and epigenomics of bladder cancer and related biomarkers, and novel agents, technologies and pathways.


  • Fellow of the Academy of Translational Medicine 2016
  • PhD in Medicine 2007
  • Membership of The Royal College of Surgeons of England 1999
  • MBChB 1995


Rik Bryan qualified in Medicine at the University of Birmingham and subsequently entered surgical training. After completing a PhD in bladder cancer biology he became a higher surgical trainee in Urology. After 4-years as a Specialist Registrar, Rik left clinical urology to assist with the set-up of the Bladder Cancer Prognosis Programme (BCPP) in the Department of Public Health, Epidemiology and Biostatistics at the University of Birmingham, and was then subsequently appointed as a Senior Research Fellow in the School of Cancer Sciences. Rik is now the Chief Investigator of BCPP, which incorporates the SELENIB clinical trial.

Rik has an interest in all aspects of bladder cancer research and leads a multidisciplinary group with a focus on translation. The particular interests of the Bladder Cancer Group include cancer genomics/epigenomics, urinary biomarkers, novel therapeutics/technologies/devices, and clinical and epidemiological research. Rik has a track record of publication in all of these areas.

The group also has an interest in upper tract urothelial cancer, and Rik is the Chief Investigator of POUT-T, the translational study linked to the POUT trial.

Postgraduate supervision

  • Intercalated BMedSci
  • MRes
  • PhD


  • Genomics and epigenomics, and associated biomarkers for non-invasive diagnosis and prognostication
  • Novel genomic platforms and approaches
  • Proteomics and urinary protein biomarkers
  • Novel therapeutics, technologies and devices and associated clinical trials
  • Tumour immunology and BCG mechanisms of action
  • Clinical, epidemiological and health economic research.

Aside from the research carried out at the University of Birmingham, the Bladder Cancer Group also has a number of important national and international collaborations with other bladder cancer investigators, including Professor Maurice Zeegers (Maastricht), Professor John Kelly (UCL), Professor Bart Kiemeney (Radboud), Professor Chris Probert (Liverpool), Dr Anne Kiltie (Oxford) and Professor Chas Bountra (Oxford).

Other activities

Aside from his bladder cancer research at the University of Birmingham, Rik also fulfils a number of other roles:

  • Member of the University of Birmingham’s Clinical Trials Oversight Committee (CTOC)
  • Member of the Bladder GeCIP, 100,000 Genomes Project
  • Trustee of the charity Action Bladder Cancer UK
  • Member of the T2 and Below Subgroup (TABS) of the NCRI Bladder & Renal Clinical Studies Group
  • Council Member and current Honorary Secretary of The Royal Society of Medicine Section of Urology
  • Member of the Trial Management Group of the Peri-Operative Chemotherapy versus Surveillance in Upper Tract Urothelial Cancer (POUT) trial
  • Member of the Trial Management Group of the Clinical Research Office of the Endourology Society (CROES) multicentre randomised trial of narrow band imaging-assisted transurethral resection (TURBT) versus conventional white light-assisted TURBT in primary non-muscle-invasive bladder cancer patients.


Recent publications


Birtle, A, Johnson, M, Chester, J, Jones, R, Dolling, D, Bryan, R, Harris, C, WInterbottom, A, Blacker, A, Catto, J, Chakraborti, P, Donovan, J, Elliott, P, French, A, Jagdev, S, Jenkins, B, Keeley, F, Kockelbergh, R, Powles, T, Wagstaff, J, Wilson, C, Todd, R, Lewis, R & Hall, E 2020, 'Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial', The Lancet, pp. 1-10.

Jochems, S, Reulen, R, Van Osch, F, Witlox, WJA, Goossens, ME, Brinkman, M, Giles, GG, Milne, RL, van den Brandt, PA, White, E, Weiderpass, E, Huybrechts, I, Hémon, B, Agudo, A, Bueno-de-Mesquita, B, Cheng, KK, van Schooten, FJ, Bryan, R, Wesselius, A & Zeegers, M 2020, 'Fruit consumption and the risk of bladder cancer: a pooled analysis by the BLadder cancer Epidemiology and Nutritional Determinants study', International Journal of Cancer.

Arnold, R, Goel, A, Ward, D, Gordon, N, Abbotts, B, Zeegers, M, Cheng, KK, James, N & Bryan, R 2020, 'Back-splicing transcript isoforms (circular RNAs) affect biologically relevant pathways and offer an additional layer of information to stratify NMIBC patients', Frontiers in Oncology.

Jeeta, R, Gordon, N, Baxter, L, Goel, A, Noyvert, B, Ott, S, Boucher, B, Humayun-Zakaria, N, Arnold, R, James, N, Zeegers, M, Cheng, KK, Bryan, R & Ward, D 2019, 'Non-coding mutations in urothelial bladder cancer: biological and clinical relevance and potential utility as biomarkers', Bladder Cancer, vol. 5, no. 4, blc190251, pp. 263-272.

Lipunova, N, Wesselius, A, Cheng, KK, van Schooten, F-J, Cazier, J-B, Bryan, R & Zeegers, M 2019, 'Systematic review: genetic associations for prognostic factors of urinary bladder cancer', Biomarkers in Cancer, vol. 11, pp. 1-9.

Yu, E, Nekeman, D, Aaronson, N, Billingham, L, James, N, Cheng, KK, Bryan, R, Wesselius, A & Zeegers, M 2019, 'Health-related quality of life around the time of diagnosis in patients with bladder cancer', BJU International , vol. 124, no. 6, pp. 984-991.

Russell, B, Liedberg, F, Shamim Khan, M, Nair, R, Thurairaja, R, Malde, S, Kumar, P, Bryan, R & Van Hemelrijck, M 2019, 'A systematic review and meta-analysis of delay to radical cystectomy and the effect on survival in bladder cancer patients', European Urology Oncology.

Lipunova, N, Wesselius, A, Cheng, KK, van Schooten, F-J, Cazier, J-B, Bryan, R & Zeegers, MP 2019, 'External replication of urinary bladder cancer prognostic polymorphisms in the UK Biobank', Frontiers in Oncology, vol. 9, 1082.

Wylie, H, Cahill, F, Santaolalla, A, Moss, CL, Enting, D, Amery, S, Chatterton, K, Khan, MS, Bryan, RT, Gillett, C, Josephs, D, Chowdhury, S, Rudman, S, Hughes, S, Relton, C & Van Hemelrijck, M 2019, 'Graham Roberts Study protocol: first 'trials within cohort study' for bladder cancer', BMJ open, vol. 9, no. 9, e029468.

van Hensbergen, M, Van Osch, F, Jochems, S, James, N, Wallace, DMA, Wesselius, A, Cheng, KK, Bryan, R & Zeegers, M 2019, 'Fluid intake and clinicopathological characteristics of bladder cancer: the West Midlands Bladder Cancer Prognosis Programme (BCPP)', European Journal of Cancer Prevention.

Ward, D, Gordon, N, Boucher, R, Pirrie, S, Baxter, L, Ott, S, Silcock, L, Whalley, C, Stockton, J, Beggs, A, Griffiths, M, Abbotts, B, Ijakipour, H, Latheef, F, Robinson, R, White, A, James, N, Zeegers, M, Cheng, KK & Bryan, R 2019, 'Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: a 23-gene panel with utility for non-invasive diagnosis and risk stratification', BJU international, vol. 124, no. 3, pp. 532-544.

Walker, A, Na, J, Browning, L, Humayun-Zakaria, N, Zeegers, M, Cheng, KK, James, N, Bryan, R, Arnold, R & Kiltie, A 2019, 'MRE11A isoform expression associated with outcome following radiotherapy in muscle-invasive bladder cancer does not alter cell survival and DNA double-strand break repair following ionising radiation', Bladder Cancer, vol. 5, no. 2, pp. 147-157.


Bessa, A, Maclennan, S, Enting, D, Bryan, R, Häggström, C & Van Hemelrijck, M 2019, 'Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy Y.C. Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol 2019;76:260–1', European urology, vol. 76, no. 2, pp. e45-e46.


Bryan, R & Kockelbergh, R 2019, 'Asymptomatic microscopic haematuria and significant urinary tract disease', Bladder Cancer, vol. 5, pp. 115-117.


Bessa, A, Maclennan, S, Enting, D, Bryan, R, Josephs, D, Hughes, S, Amery, S, Khan, S, Malde, S, Nair, R, Cahill, F, Wylie, H, Thurairaja, R, Chatterton, K, Kinsella, N, Häggström, C & Van Hemelrijck, M 2019, 'Consensus in bladder cancer research priorities between patients and healthcare professionals using a four-stage modified Delphi method', European urology, vol. 76, no. 2, pp. 258-259.

View all publications in research portal


Bladder Cancer